Zuranolone
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 166 publications
Zuranolone mitigates delirium-like bispectral EEG changes, behavioral deficits, and neuroinflammation across surgical and inflammatory mouse models and age groups.
Journal: bioRxiv : the preprint server for biology
Published: June 04, 2026
Pharmacotherapeutic approaches to treating postpartum depression: a focus on GABAA receptor positive allosteric modulators.
Journal: Expert opinion on pharmacotherapy
Published: May 18, 2026
Updated guidelines for pharmacologic treatment of perinatal depression: Understanding medication options.
Journal: Cleveland Clinic journal of medicine
Published: April 01, 2026
Next-Generation Pharmacotherapy for Depressive Disorders: From Novel Compounds to Optimized Use of Available Drugs.
Journal: Drug design, development and therapy
Published: March 24, 2026
ACOG Clinical Practice Update, Zuranolone and Brexanolone for the Treatment of Postpartum Depression: Correction.
Journal: Obstetrics and gynecology
Published: March 19, 2026
▼Zuranolone for the treatment of moderate or severe postnatal depression.
Journal: Drug and therapeutics bulletin
Published: March 04, 2026
Global Perspectives on CNS Drug Innovation: Achievements, Barriers, and Priorities for the Next Decade.
Journal: The international journal of neuropsychopharmacology
Published: February 12, 2026
Response to Durability of zuranolone in postpartum depression versus major depressive disorder.
Journal: Psychiatry and clinical neurosciences
Published: February 09, 2026
Addressing the Global Mental Health Crisis: How a Human Rights Approach Can Help End the Search for Pharmaceutical Magic Bullets.
Journal: Health and human rights
Published: January 15, 2026
Current treatment options for perinatal depression.
Journal: Current opinion in obstetrics & gynecology
Published: January 14, 2026
Last Updated: 06/30/2026